- Home
- ZYME vs SANA Comparison
ZYME vs SANA Comparison
Compare ZYME & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- SANA
- Stock Information
- Founded
- ZYME 2003
- SANA 2018
- Country
- ZYME United States
- SANA United States
- Employees
- ZYME N/A
- SANA N/A
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- SANA Medicinal Chemicals and Botanical Products
- Sector
- ZYME Health Care
- SANA Health Care
- Exchange
- ZYME Nasdaq
- SANA Nasdaq
- Market Cap
- ZYME 968.5M
- SANA 983.4M
- IPO Year
- ZYME 2017
- SANA 2021
- Fundamental
- Price
- ZYME $15.93
- SANA $3.23
- Analyst Decision
- ZYME Buy
- SANA Strong Buy
- Analyst Count
- ZYME 7
- SANA 5
- Target Price
- ZYME $20.00
- SANA $8.75
- AVG Volume (30 Days)
- ZYME 446.6K
- SANA 4.1M
- Earning Date
- ZYME 10-30-2025
- SANA 11-07-2025
- Dividend Yield
- ZYME N/A
- SANA N/A
- EPS Growth
- ZYME N/A
- SANA N/A
- EPS
- ZYME N/A
- SANA N/A
- Revenue
- ZYME $122,867,000.00
- SANA N/A
- Revenue This Year
- ZYME $107.76
- SANA N/A
- Revenue Next Year
- ZYME $2.35
- SANA N/A
- P/E Ratio
- ZYME N/A
- SANA N/A
- Revenue Growth
- ZYME 95.94
- SANA N/A
- 52 Week Low
- ZYME $9.03
- SANA $1.26
- 52 Week High
- ZYME $17.70
- SANA $7.30
- Technical
- Relative Strength Index (RSI)
- ZYME 64.90
- SANA 48.58
- Support Level
- ZYME $14.88
- SANA $2.87
- Resistance Level
- ZYME $16.37
- SANA $3.42
- Average True Range (ATR)
- ZYME 0.65
- SANA 0.24
- MACD
- ZYME 0.11
- SANA 0.04
- Stochastic Oscillator
- ZYME 84.12
- SANA 63.89
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.